| Composition of Certain Financial Statement Captions |
|
|
|
|
|
|
|
|
|
(In thousands) |
September 30,
2016 |
|
December 31,
2015 |
Accounts receivable, net |
|
|
|
Accounts receivable |
$ |
264,957 |
|
|
$ |
219,043 |
|
Less: allowance for doubtful accounts |
(41,130 |
) |
|
(25,168 |
) |
|
$ |
223,827 |
|
|
$ |
193,875 |
|
Inventories, net |
|
|
|
Consumable supplies |
$ |
22,693 |
|
|
$ |
22,265 |
|
Finished products |
14,030 |
|
|
13,404 |
|
Work in-process |
1,596 |
|
|
1,215 |
|
Raw materials |
6,014 |
|
|
3,848 |
|
Less: inventory reserve |
(1,147 |
) |
|
(1,051 |
) |
|
$ |
43,186 |
|
|
$ |
39,681 |
|
Other current assets and prepaid expenses |
|
|
|
Taxes recoverable |
56,566 |
|
|
3,076 |
|
Other receivables |
16,020 |
|
|
11,946 |
|
Prepaid supplies |
11,428 |
|
|
8,773 |
|
Prepaid insurance |
5,520 |
|
|
2,206 |
|
Other |
874 |
|
|
903 |
|
|
$ |
90,408 |
|
|
$ |
26,904 |
|
Intangible assets, net: |
|
|
|
Customer relationships |
$ |
445,743 |
|
|
$ |
449,972 |
|
Technologies |
339,333 |
|
|
151,709 |
|
Trade names |
50,476 |
|
|
50,416 |
|
Licenses |
23,506 |
|
|
23,432 |
|
Covenants not to compete |
16,361 |
|
|
8,612 |
|
Product registrations |
7,911 |
|
|
7,512 |
|
Other |
4,430 |
|
|
5,600 |
|
Less: accumulated amortization |
(105,870 |
) |
|
(59,101 |
) |
|
$ |
781,890 |
|
|
$ |
638,152 |
|
Accrued expenses: |
|
|
|
Deferred revenue |
$ |
72,559 |
|
|
$ |
70,246 |
|
Employee benefits |
33,608 |
|
|
29,751 |
|
Clinical trials |
10,056 |
|
|
2,505 |
|
Taxes payable |
16,733 |
|
|
7,605 |
|
Contingent consideration |
5,211 |
|
|
22,164 |
|
Capital leases short-term |
3,062 |
|
|
5,373 |
|
Milestone payment |
4,966 |
|
|
5,000 |
|
Professional fees |
2,259 |
|
|
1,506 |
|
Other |
37,622 |
|
|
23,749 |
|
|
$ |
186,076 |
|
|
$ |
167,899 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands) |
September 30,
2016 |
|
December 31,
2015 |
Other long-term liabilities: |
|
|
|
Deferred revenue |
$ |
107,817 |
|
|
$ |
162,634 |
|
Line of credit |
38,444 |
|
|
72,107 |
|
Contingent consideration |
38,532 |
|
|
32,258 |
|
Mortgages and other debts payable |
2,243 |
|
|
2,523 |
|
Capital leases long-term |
7,527 |
|
|
9,285 |
|
Other |
9,531 |
|
|
13,663 |
|
|
$ |
204,094 |
|
|
$ |
292,470 |
|
|
| Changes in Goodwill |
The following table reflects the changes in Goodwill during the nine months ended September 30, 2016.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016 |
(In thousands) |
Balance at January 1st |
|
Purchase accounting adjustments |
|
Foreign exchange |
|
Balance at September 30th |
Pharmaceuticals |
|
|
|
|
|
|
|
CURNA |
$ |
4,827 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
4,827 |
|
EirGen |
81,139 |
|
|
— |
|
|
2,364 |
|
|
83,503 |
|
FineTech |
11,698 |
|
|
— |
|
|
— |
|
|
11,698 |
|
OPKO Chile |
4,517 |
|
|
— |
|
|
343 |
|
|
4,860 |
|
OPKO Biologics |
139,784 |
|
|
— |
|
|
— |
|
|
139,784 |
|
OPKO Health Europe |
7,191 |
|
|
— |
|
|
201 |
|
|
7,392 |
|
OPKO Renal |
2,069 |
|
|
— |
|
|
— |
|
|
2,069 |
|
Transition Therapeutics |
— |
|
|
3,453 |
|
|
(16 |
) |
|
3,437 |
|
|
|
|
|
|
|
|
|
Diagnostics |
|
|
|
|
|
|
|
Bio-Reference |
441,158 |
|
|
(49,167 |
) |
|
— |
|
|
391,991 |
|
OPKO Diagnostics |
17,977 |
|
|
— |
|
|
— |
|
|
17,977 |
|
OPKO Lab |
32,988 |
|
|
— |
|
|
— |
|
|
32,988 |
|
|
$ |
743,348 |
|
|
$ |
(45,714 |
) |
|
$ |
2,892 |
|
|
$ |
700,526 |
|
|